021-51111890
购物车（）
sales@molnova.cn
Lenvatinib mesylate
CAS No. 857890-39-2
Lenvatinib mesylate ( E7080 mesylate )
产品货号. M21828 CAS No. 857890-39-2
Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 25MG | ￥446 | 有现货 |
|
| 50MG | ￥648 | 有现货 |
|
| 100MG | ￥915 | 有现货 |
|
| 200MG | ￥1361 | 有现货 |
|
| 500MG | ￥2292 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Lenvatinib mesylate
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.
-
产品描述Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.
-
同义词E7080 mesylate
-
通路Angiogenesis
-
靶点VEGFR
-
受体——
-
研究领域——
-
适应症——
化学信息
-
CAS Number857890-39-2
-
分子量522.96
-
分子式C22H23ClN4O7S
-
纯度>98% (HPLC)
-
溶解度DMSO : 7.35 mg/mL (14.05 mM; Need ultrasonic)
-
SMILESO=C(C1=C(OC)C=C2N=CC=C(OC3=CC=C(NC(NC4CC4)=O)C(Cl)=C3)C2=C1)N.OS(=O)(C)=O
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Kudo M, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellularcarcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173.
2. Suyama K, et al. Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers. Cancer Control. 2018 Jan-Dec;25(1):1073274818789361.
产品手册
关联产品
-
BFH-772
A potent, selective and orally active VEGFR2 tyrosine kinase inhibitor with IC50 of 3 nM.
-
Fargesin
Fargesin as a potential β1AR antagonist through cAMP/PKA pathway could protect against myocardial ischemia/reperfusion injury in rats.
-
AG-13958
AG-13958 (AG-013958) a potent VEGFR tyrosine kinase inhibitor ?for the treatment of age-related macular degeneration.
